{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:47:23Z","timestamp":1793836043702,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.urolonc.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:24:37Z","timestamp":1710282277000},"page":"162.e11-162.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4562-4824","authenticated-orcid":false,"given":"Vincent E","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0947-407X","authenticated-orcid":false,"given":"Ryan M","family":"Antar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3480-2741","authenticated-orcid":false,"given":"Luca","family":"Bertozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2240-6875","authenticated-orcid":false,"given":"Arthur","family":"Drouaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7194-7873","authenticated-orcid":false,"given":"Sarah","family":"Azari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-3315","authenticated-orcid":false,"given":"Sean M","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2423-072X","authenticated-orcid":false,"given":"Michael J","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.urolonc.2024.02.007_bib0001","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines\u00ae Insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.urolonc.2024.02.007_bib0002","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.eururo.2022.10.004","article-title":"Upfront cytoreductive nephrectomy for metastatic renal cell carcinoma treated with immune checkpoint inhibitors or targeted therapy: an observational study from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"83","author":"Bakouny","year":"2023","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.02.007_bib0003","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1308\/rcsann.2017.0031","article-title":"Radical prostatectomy for locally advanced and metastatic prostate cancer","volume":"99","author":"Veeratterapillay","year":"2017","journal-title":"Ann R Coll Surg Engl"},{"issue":"3","key":"10.1016\/j.urolonc.2024.02.007_bib0004","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4111\/icu.20230058","article-title":"Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: an updated systematic review and meta-analysis","volume":"64","author":"Chung","year":"2023","journal-title":"Investig Clin Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.02.007_bib0005","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"issue":"29","key":"10.1016\/j.urolonc.2024.02.007_bib0006","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2016.66.7352","article-title":"Efficacy of high-intensity local treatment for metastatic urothelial carcinoma of the bladder: a propensity score-weighted analysis from the National Cancer Data Base","volume":"34","author":"Seisen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.02.007_bib0007","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.euf.2016.12.003","article-title":"Impact of baseline characteristics on the survival benefit of high-intensity local treatment in metastatic urothelial carcinoma of the bladder","volume":"4","author":"Vetterlein","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"2","key":"10.1016\/j.urolonc.2024.02.007_bib0008","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.euo.2018.02.001","article-title":"Location of metastatic bladder cancer as a determinant of in-hospital mortality after radical cystectomy","volume":"1","author":"Zaffuto","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.02.007_bib0009","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CMAR.S148856","article-title":"Prognostic value of site-specific metastases and therapeutic roles of surgery for patients with metastatic bladder cancer: a population-based study","volume":"9","author":"Dong","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.urolonc.2024.02.007_bib0010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.euo.2019.06.014","article-title":"Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an International, Multicenter, Multidisciplinary Database","volume":"3","author":"Moschini","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2024.02.007_bib0011","unstructured":"American College of Surgeons. Standards for Oncology Registry Entry (STORE): revised for 2022. ACS 2023. https:\/\/www.facs.org\/media\/j5bp1dn4\/store-2023-final-version-06282023.pdf."},{"key":"10.1016\/j.urolonc.2024.02.007_bib0012","unstructured":"American College of Surgeons. Facility Oncology Registry Data Standards (FORDS): revised for 2016. ACS. 2023. https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/ncdb-call-for-data\/fordsmanual\/."},{"issue":"3","key":"10.1016\/j.urolonc.2024.02.007_bib0013","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2307\/2533848","article-title":"Assessing the sensitivity of regression results to unmeasured confounders in observational studies","volume":"54","author":"Lin","year":"1998","journal-title":"Biometrics"},{"key":"10.1016\/j.urolonc.2024.02.007_bib0014","unstructured":"IBM Corp. Released 2022. IBM SPSS statistics, version 29.0. Chicago, IL: IBM Corp. ibm.com\/spss. Accessed July 1, 2023."},{"issue":"4","key":"10.1016\/j.urolonc.2024.02.007_bib0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","article-title":"The role of surgery in metastatic bladder cancer: a systematic review","volume":"73","author":"Abufaraj","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.02.007_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.clgc.2016.04.001","article-title":"Cytoreductive nephrectomy in metastatic renal cell carcinoma treated with targeted therapies: a systematic review with a meta-analysis","volume":"14","author":"Petrelli","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"25","key":"10.1016\/j.urolonc.2024.02.007_bib0017","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.02.007_bib0018","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1803675","article-title":"Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma","volume":"379","author":"M\u00e9jean","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.urolonc.2024.02.007_bib0019","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2024.02.007_bib0020","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","article-title":"LBA6 EV-302\/KEYNOTE-A39: open-label, randomized phase Ill study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC)","volume":"34","author":"Powles","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.02.007_bib0021","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"issue":"7069","key":"10.1016\/j.urolonc.2024.02.007_bib0022","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nature04186","article-title":"VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche","volume":"438","author":"Kaplan","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.urolonc.2024.02.007_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/PAP.0000000000000219","article-title":"Paget's \u201cseed and soil\u201d theory of cancer metastasis: an idea whose time has come","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv Anat Pathol"},{"issue":"10139","key":"10.1016\/j.urolonc.2024.02.007_bib0024","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2024.02.007_bib0025","article-title":"A model for identifying optimal patients for primary tumor resection in patients with metastatic bladder cancer","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.02.007_bib0026","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2023.1121357","article-title":"Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: a retrospective single-center study","volume":"10","author":"Bai","year":"2023","journal-title":"Front Surg"},{"issue":"1","key":"10.1016\/j.urolonc.2024.02.007_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","article-title":"Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study","volume":"67","author":"Fossati","year":"2015","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.urolonc.2024.02.007_bib0028","doi-asserted-by":"crossref","first-page":"28408","DOI":"10.18632\/oncotarget.16083","article-title":"The prognostic value of histological subtype in patients with metastatic bladder cancer","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.urolonc.2024.02.007_bib0029","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/cncr.28146","article-title":"Nomogram for predicting survival in patients with unresectable and\/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy","volume":"119","author":"Galsky","year":"2013","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2024.02.007_bib0030","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00345-019-02693-y","article-title":"The role of metastatic burden in cytoreductive\/consolidative radical cystectomy","volume":"37","author":"Li","year":"2019","journal-title":"World J Urol"},{"issue":"24","key":"10.1016\/j.urolonc.2024.02.007_bib0031","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1002\/cam4.3560","article-title":"The role of surgery on the primary tumor site in bladder cancer with distant metastasis: significance of histology type and metastatic pattern","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"issue":"18","key":"10.1016\/j.urolonc.2024.02.007_bib0032","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924003375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T22:43:06Z","timestamp":1712875386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924003375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1078143924003375"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.02.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of cytoreductive radical cystectomy in metastatic urothelial bladder cancer based on site and number of metastases","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}